Biomarin Pharmaceutical Inc (BMRN.OQ)
BMRN.OQ on NASDAQ Stock Exchange Global Select Market
89.09USD
12:45am IST
89.09USD
12:45am IST
Change (% chg)
$-1.57 (-1.73%)
$-1.57 (-1.73%)
Prev Close
$90.66
$90.66
Open
$90.12
$90.12
Day's High
$91.15
$91.15
Day's Low
$88.68
$88.68
Volume
171,120
171,120
Avg. Vol
386,472
386,472
52-wk High
$106.69
$106.69
52-wk Low
$75.84
$75.84
Revenue & Earnings Per Share
| Revenue* | Earnings Per Share** | ||
|---|---|---|---|
| FY 2018 | Sep '18 | 391.71 | -0.071 |
| Jun '18 | 372.85 | -0.095 | |
| Mar '18 | 373.45 | -0.277 | |
| FY 2017 | Dec '17 | 358.30 | -0.052 |
| Sep '17 | 334.15 | -0.072 | |
| Jun '17 | 317.45 | -0.211 | |
| Mar '17 | 303.74 | -0.094 |
*Note: Units in Millions ofU.S. Dollars
**Note: Units in U.S. Dollars
Consensus Estimates Analysis
| # of Estimates | Mean | High | Low | 1 Year Ago | |
|---|---|---|---|---|---|
| SALES (in millions) | |||||
| Quarter Ending Mar-19 | 17 | 404.61 | 444.00 | 381.00 | 398.81 |
| Quarter Ending Jun-19 | 17 | 425.68 | 442.20 | 401.00 | 420.94 |
| Year Ending Dec-19 | 25 | 1,726.48 | 1,800.00 | 1,632.00 | 1,716.37 |
| Earnings (per share) | |||||
| Quarter Ending Mar-19 | 15 | -0.07 | 0.13 | -0.26 | 0.06 |
| Quarter Ending Jun-19 | 15 | -0.02 | 0.10 | -0.20 | 0.11 |
| Year Ending Dec-19 | 21 | -0.03 | 0.62 | -0.74 | 0.60 |
| LT Growth Rate (%) | 1 | 47.20 | 47.20 | 47.20 | -- |
Sales and Profit Figures in US Dollar (USD);
Valuation Ratios
| Company | industry | sector | ||
|---|---|---|---|---|
| P/E Ratio (TTM) | -- | 30.48 | 33.70 | |
| P/E High - Last 5 Yrs. | -- | 44.98 | 49.87 | |
| P/E Low - Last 5 Yrs. | -- | 23.63 | 24.25 | |
| Beta | 1.80 | 0.90 | 0.90 | |
| Price to Sales (TTM) | 13.83 | 4.12 | 6.29 | |
| Price to Book (MRQ) | 5.94 | 5.10 | 5.26 | |
| Price to Tangible Book (MRQ) | 8.07 | 5.85 | 6.77 | |
| Price to Cash Flow (TTM) | -- | 24.01 | 24.98 | |
| % Owned Institutions | -- | 0.90 | 1.69 | |
Dividends
| Company | industry | sector | ||
|---|---|---|---|---|
| Dividend Yield | -- | 1.49 | 1.40 | |
| Dividend Yield - 5 Year Avg | -- | 1.51 | 1.42 | |
| Dividend 5 Year Growth Rate | -- | 4.15 | 4.85 | |
| Payout Ratio(TTM) | -- | 43.91 | 41.03 | |
Growth Rates
| Company | industry | sector | ||
|---|---|---|---|---|
| Sales (MRQ) vs Qtr. 1 Yr. Ago | 5.77 | 4.31 | 12.76 | |
| Sales (TTM) vs TTM 1 Yr. Ago | 23.36 | 4.07 | 5.84 | |
| Sales - 5 Yr. Growth Rate | 20.40 | 10.91 | 11.23 | |
| EPS (MRQ) vs Qtr. 1 Yr. Ago | 91.80 | 44.94 | 47.15 | |
| EPS (TTM) vs TTM 1 Yr. Ago | 68.48 | -- | -- | |
| EPS - 5 Yr. Growth Rate | -- | 10.31 | 10.85 | |
| Capital Spending - 5 Yr. Growth Rate | -0.77 | 15.88 | 15.20 | |
Financial Strength
| Company | industry | sector | |
|---|---|---|---|
| Quick Ratio (MRQ) | 2.75 | 2.15 | 2.25 |
| Current Ratio (MRQ) | 3.90 | 2.97 | 3.08 |
| LT Debt to Equity (MRQ) | 24.19 | 8.85 | 11.38 |
| Total Debt to Equity (MRQ) | 24.19 | 12.89 | 16.12 |
| Interest Coverage (TTM) | -4.81 | 33.79 | 29.47 |
Profitability Ratios
| Company | industry | sector | ||
|---|---|---|---|---|
| Gross Margin (TTM) | 81.59 | 53.68 | 53.81 | |
| Gross Margin - 5 Yr. Avg. | 82.35 | 51.67 | 52.18 | |
| EBITD Margin (TTM) | -9.95 | -- | -- | |
| EBITD - 5 Yr. Avg | -15.34 | 17.96 | 12.87 | |
| Operating Margin (TTM) | -17.38 | 14.31 | 6.19 | |
| Operating Margin - 5 Yr. Avg. | -33.82 | 14.24 | 8.31 | |
| Pre-Tax Margin (TTM) | -19.05 | 14.85 | 7.15 | |
| Pre-Tax Margin - 5 Yr. Avg. | -36.93 | 14.68 | 8.61 | |
| Net Profit Margin (TTM) | -14.54 | 11.08 | 3.29 | |
| Net Profit Margin - 5 Yr. Avg. | -32.24 | 11.02 | 4.89 | |
| Effective Tax Rate (TTM) | -- | 23.02 | 22.91 | |
| Effective Tax Rate - 5 Yr. Avg. | -- | 23.16 | 23.38 | |
Efficiency
| Company | industry | sector | ||
|---|---|---|---|---|
| Revenue/Employee (TTM) | 523,846 | 957,633,954 | 842,388,426 | |
| Net Income/Employee (TTM) | -76,158 | 113,563,169 | 99,841,620 | |
| Receivable Turnover (TTM) | 5.31 | 5.71 | 5.71 | |
| Inventory Turnover (TTM) | 0.58 | 2.61 | 3.47 | |
| Asset Turnover (TTM) | 0.34 | 0.97 | 0.93 | |
Management Effectiveness
| Company | industry | sector | ||
|---|---|---|---|---|
| Return on Assets (TTM) | -4.91 | 11.52 | 11.06 | |
| Return on Assets - 5 Yr. Avg. | -9.67 | 12.92 | 12.20 | |
| Return on Investment (TTM) | -5.48 | 14.95 | 14.45 | |
| Return on Investment - 5 Yr. Avg. | -10.78 | 16.84 | 15.87 | |
| Return on Equity (TTM) | -7.41 | 16.27 | 15.96 | |
| Return on Equity - 5 Yr. Avg. | -15.23 | 17.77 | 17.00 | |
| 1 Year | 3 Year | 5 Year | |
|---|---|---|---|
| Sales % | 25.50 | 26.75 | 20.40 |
| EPS (TTM) % | -253.66 | -- | -- |
| Dividend % | -- | -- | -- |
Note: Units in Millions of US Dollars
Performance for Biomarin Pharmaceutical Inc
| Period | % Actual |
% vs. S&P 500 |
Rank In Industry |
Industry Rank |
|---|---|---|---|---|
| 4 Week | 5.23 | 1.60 | 99 | 22 |
| 13 Week | 4.75 | -0.35 | 99 | 39 |
| 26 Week | 7.80 | -0.39 | 99 | 33 |
| 52 Week | 2.35 | -13.25 | 99 | 9 |
| YTD | 14.45 | 0.51 | 99 | 26 |
Note:: Rank is a percentile that ranges from 0 to 99, with 99 = best.
- Catalyst Pharma sees net price of drug, once free, topping $300,000
- Catalyst Pharma sees net price of drug, once free, topping $300,000
- Catalyst Pharma sees net price of drug, once free, topping $300,000
- BioMarin sets stage early for hemophilia cure off-Broadway
- BioMarin sets stage early for haemophilia cure off-Broadway
Institutional Holders
| % Shares Owned: | 0.00% |
| # of Holders: | 672 |
| Total Shares Held: | 186,006,048 |
| 3 Mo. Net Change: | -1,802,248 |
| # New Positions: | 59 |
| # Closed Positions: | 58 |
| # Increased Positions: | 261 |
| # Reduced Positions: | 288 |
| # Net Buyers: | -27 |
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.